Share this article and save a life!
129 million patient records just became accessible to pharma AI.
Oracle dropped a bombshell this week.
Their new Life Sciences AI Data Platform, announced January 29, connects something unprecedented: real-world data from 129 million de-identified EHR records directly to pharmaceutical R&D teams.
Think about what this means:
• Clinical trials could identify eligible patients in days, not months
• Drug safety signals detected years earlier through real-world evidence
• Rare disease research finally has the scale it needs
• Post-market surveillance happens in real-time, not retrospectively
But here’s what makes me pause.
We’re handing massive amounts of patient data, even de-identified, to an industry that hasn’t always prioritized patient interests first.
Yes, the potential is enormous. Finding the next breakthrough therapy faster. Understanding why drugs work for some patients but not others. Preventing the next Vioxx before it happens.
Yet I can’t help wondering: Where’s the patient voice in this?
Who ensures this data serves public health, not just profit margins? How do we guarantee insights from our collective medical histories benefit everyone, not just those who can afford cutting-edge treatments?
The technology is revolutionary. The governance? That’s still stuck in the past.
Healthcare leaders, we need to shape this conversation now. Before the algorithms decide for us.
What safeguards would you demand before supporting this level of data sharing?
♻️ Repost if pharma AI needs patient-centered governance
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
